Exam Questions Flashcards

1
Q

Which glomerulonephritis is most likely to rapidly recur in a renal allograft?

A

FSGS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Pathophysiology of vascular calcification in CKD

A
  • Vascular calcification in CKD involves major disturbance of the calcium phosphate homeostasis and reductions in serum fetuin and pyrophosphate levels.
  • In terms of pathobiology, vascular smooth muscle cell (VSMC) apoptosis and osteochondrogenic metaplasia is driven by hyperphosphataemia, worsened by iatrogenic
    hypoparathyroidism and low-turnover bone disease.
  • Whilst antecedent diabetes mellitus, hypertension, dyslipidaemia and the metabolic syndrome continue
    to contribute to arteriosclerosis, HYPERPHOSPHATAEMIA, REDUCE KLOTHO AND IMPAIRED SOFT TISSUE CALCIFICATION DEFENCES are key pathophysiological
    components of this condition.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Hb Aims of EPO and why

A

Aim Hb < 115

Not > 130 as risk of stroke, headache, high BP, VTE, vascular access thrombosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Risk factors for developing BK virus

A

The risk factors associated with BKN include:
• Aggressive immunosuppressive treatment during the acute rejection, especially the usage of monoclonal antibodies such as anti-thymocyte globulin (ATG)
• Older recipient age
• Female donor
• HLA DR mismatching.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

In developed countries, which one of the following bone disorders is most
frequent in patients receiving maintenance haemodialysis?
A. Osteitis fibrosa cystica
B. Adynamic bone disease
C. Osteomalacia
D. Dialysis-related amyloidosis
E. Aluminium bone disease

A

B. Adynamic bone disease

Adynamic bone disease (ABD) is a variety of renal osteodystrophy characterized by reduced osteblasts and osteoclasts, no accumulation of osteoid and markedly low bone turnover.

Osteitis fibrosa cystica (OFC) is a skeletal disorder caused by an overproduction of parathyroid hormone from the overactive parathyroid glands. Osteitis fibrosa cystica is the late manifestation of the hyperparathyroidism.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Features of dialysis related amyloidosis

A
  • Dialysis-related amyloidosis (DRA) is a disorder caused by deposition of beta-2 microglobulin as amyloid deposits.
  • The clearance of beta-2 microglobulin is diminished with decreasing renal function.
  • DRA is relatively common in patients, especially older adults, who have been on haemodialysis for more than 5 years. Newer haemodialysis membranes, as well
    as peritoneal dialysis, can facilitate a greater clearance of beta-2 microglobulin, but are insufficient to keep blood levels normal.
  • Renal transplantation can ameliorate the condition.
  • Carpal tunnel syndrome and shoulder pain are the most common presentations of DRA.
  • The bone lesions are typically cystic and seen at the end of long bones.
  • The cystic lesions contain amyloid, enlarge with time and may lead to pathological fractures of carpal bones, the femur and humeral heads, fingers, acetabulum and
    distal radius.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q
Which one of the following is NOT a risk factor for contrast-induced acute
kidney injury?
A. Congestive heart failure
B. Metformin
C. Multiple myeloma
D. Non-steroidal anti-inflammatory drugs
E. Sepsis
A

B. Metformin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Mechanism of action of mycophenolate

A
PURINE SYNTHESIS INHIBITOR 
Mycophenolate mofetil (MMF, CellCept) is a prodrug of mycophenolic acid (MPA), an inhibitor of inosine-5'-monophosphate dehydrogenase. MPA depletes guanosine nucleotides preferentially in T and B lymphocytes and inhibits their proliferation, thereby suppressing cell-mediated immune responses and antibody formation

Mycophenolate is listed as a category D drug. It
increases first-trimester pregnancy loss and congenital malformation, including cleft lip and palate, and anomalies in distal limbs and heart, and should be
discontinued.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

In renal transplant patients, what combination of immunosuppressive can be given

A

Combination of calcineurin inhibitor, azathioprine and

prednisolone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

A 54-year-old man on regular haemodialysis presents with lower back pain
and fever. You request a magnetic resonance imaging (MRI) study of the spine,
but request that gadolinium not be used during the test because of concern
about:
A. Contrast-induced nephropathy
B. Nephrogenic systemic fibrosis
C. High incidence of allergy reaction to gadolinium among patients on
haemodialysis
D. Heavy metal toxicity
E. Systemic sclerosis

A

B. Nephrogenic systemic fibrosis

  • Nephrogenic systemic fibrosis (NSF) is seen only in patients with kidney failure and is characterised by symmetrical skin involvement with extensive waxy thickening and hardening of the extremities and torso. Can also cause fibrosis of deeper structures, eg: lungs.
  • Histologically it is characterised by marked expansion and fibrosis of the dermis with CD34-positive
    fibrocytes.
  • This condition is associated with exposure to gadolinium, which is a hyperosmolar contrast agent used primarily during magnetic resonance imaging (MRI) or
    angiography (MRA) studies. Free gadolinium is highly toxic and insoluble in water and so it has to be chelated for human administration. These gadolinium chelates
    are excreted almost exclusively by the kidneys.
  • Gadolinium should be avoided in patients with a glomerular filtration rate (GFR) of less than 30 mL/min.
  • The latent period between gadolinium exposure and disease onset is usually 1–4 weeks. Skin changes and joint contractures can occur. Since the recognition
    of the dangers of gadolinium in patients with impaired renal function, the incidence of NSF has dramatically declined.
  • In patients with significant renal impairment (GFR <30 mL/min) in whom the use of gadolinium is imperative, such as liver transplant work-up, haemodialysis
    after the exposure should be considered. Gadolinium chelates have a molecular weight of 500–1000 kDa and are removed by haemodialysis. A single conventional haemodialysis will remove 75% of a dose. A second treatment will remove 93% of a dose. Minimum adequate doses of gadolinium should be used.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the most important risk factor for the development of post-transplant
lymphoproliferative disorder (PTLD) in solid organ transplantation?
A. Kidney transplantation as opposed to other solid organ transplants
B. Epstein–Barr virus status mismatch between recipient and donor
C. Use of the monoclonal anti-CD52 antibody, alemtuzumab
D. Use of sirolimus
E. Previous infection with cytomegalovirus (CMV)

A

B. Epstein–Barr virus status mismatch between recipient and donor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

A 48-year-old man presents with severe right-sided loin pain radiating to the
scrotum. A computed tomography scan demonstrates a 4-mm distal ureteric
calculus. Which one of the following treatments has been shown to increase the
chances of stone passage?
A. Frusemide
B. Tamsulosin
C. Atenolol
D. Intravenous saline
E. Thiazide diuretics

A

B. Tamsulosin

Alpha-1-adrenergic receptor antagonists such as tamsulosin can promote the chances of stone passage. Alpha-1 receptors are located in the human ureter, especially the distal ureter, and alpha-blockers have
been demonstrated to increase expulsion rates of distal ureteral stones, decrease time to expulsion and decrease need for analgesia during stone passage. Up to
98% of small stone of less than 5 mm may pass spontaneously.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Post-transplantation lymphoproliferative disease (PTLD)

A
  • Post-transplantation lymphoproliferative disease (PTLD) carries a high mortality
  • Most cases of PTLD are induced by Epstein–Barr virus (EBV). A seronegative renal transplant recipient who receives a seropositive kidney is at high risk of developing PTLD.

Treatment:
The reduction of immunosuppression forms the cornerstone of all treatment and may be sufficient by itself, with a complete remission rate of 63% in some reports.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

A 38-year-old woman presented with bilateral red eyes, which was diagnosed as anterior uveitis. This was treated with topical steroids and improved. One month later, she represented with acute deterioration of her renal function
(creatinine 250 μmol/L, reference range: 60–100 μmol/L). Moderate proteinuria
(1.5 g/24 h) and urine eosinophilia were detected. There are no significant dysmorphic red blood cells or casts in the urinary sediment. Renal ultrasound showed
both kidneys were normal in size and appearance. She had a percutaneous renal biopsy. What is the biopsy likely to show?
A. Membranous nephropathy
B. Minimal change disease
C. Tubulointerstitial nephritis
D. Focal and segmental glomerulosclerosis
E. IgA nephropathy

A

C. Tubulointerstitial nephritis

  • The patient in the vignette has tubulointerstitial nephritis and uveitis (TINU) syndrome
  • The proposed diagnostic criteria for definite TINU specifies that affected patients’ renal biopsy should be consistent with acute tubulointersitial nephritis (ATIN) and the onset of bilateral uveitis 2 months or less before or less than 12 months after ATIN.
  • Most patients with TINU are adolescents and young women. Renal disease in these patients is usually self-limited but some may develop progressive renal
    failure. Histocompatibility leucocyte antigen (HLA) haplotype DQA101/DQB105/ DRB1*01 may be of importance in TINU susceptibility.
  • ATIN in this syndrome is typically treated with prednisolone and good results have been reported.
  • Topical and systemic corticosteroids have been used for uveitis with success. Recurrences of uveitis are common.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Glomerular diseases include a wide range of immune and non-immune insults
that may target and injure the podocyte. Which of these is true?
A. The degree of podocytopenia predicts the progression of diabetic kidney
disease
B. Podocyte proliferation is a feature of minimal change disease
C. Foot process effacement is seen in membranous nephropathy
D. Expression of slit diaphragm proteins are not altered in nephrotic
disorders
E. Podocytes do not undergo programmed cell death

A

A. The degree of podocytopenia predicts the progression of diabetic kidney
disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Prognostic risk factors for progression of idiopathic membranous nephropathy

A

Prognostic risk factors for progression of idiopathic membranous nephropathy include:
• Greater degree and duration of proteinuria
• Impaired kidney function at presentation
• Hypertension
• Male sex and age more than 50 years
• Non-Asian race
• Biopsy features of glomerulosclerosis, stage III/IV disease, tubulointerstitial fibrosis.

17
Q

Aldosterone stimulates which part of the renal tubule to reabsorb sodium?

A

Cortical collecting duct

18
Q

Atrial natriuretic peptide (ANP) affects which part of the renal tubule to inhibit sodium reabsorption?

A

Medullary collecting duct

Many of the cells in the cardiac atria secrete a peptide hormone called atrial natriuretic peptide (ANP). ANP acts directly on the inner medullary collecting ducts
to inhibit sodium reabsorption. The major stimulus for increased secretion of ANP is distension of the atria, which occurs during plasma volume expansion

19
Q

What does hepcidin do?

A

It inhibits ferroportin so that iron can no longer be transported into the bloodstream

Note:

  • Ferroportin transports iron from the enterocyte into the blood
  • Transferrin carriers iron in the blood to its target organs

Decrease iron absorption (by degrading ferroportin) and decrease iron release (from macrophages) = anemia of
chronic disease

20
Q

Iron absorption

A

Absorption of iron occurs in the duodenum and upper jejunum, and depends on specific carrier mechanisms. The transporter protein Divalent Metal Transporter 1 (DMT1), located on the apical surface of enterocytes, facilitates uptake of non-haem ferrous iron (Fe2+) from the intestinal lumen.

Ferric iron (Fe3+) in the intestinal lumen must be reduced to ferrous iron (Fe2+) by duodenal cytochrome B reductase (DcytB) before uptake by DMT1.

The iron within enterocytes can either be stored as ferritin, or transferred into the bloodstream via the protein ferroportin. Once in the blood, iron is bound by the transport protein transferrin, and is mostly transported to bone marrow for erythropoiesis. Some is taken up by macrophages in the reticuloendothelial system as a storage pool.

21
Q

How is vitamin D synthesised?

A
  • Provitamin D3 is synthesised from cholesterol in the liver and the skin
  • UV radiation converts provitamin D3 to vitamin D3
  • Vitamin D3 is hydroxylated to 25-hydroxycholecalciferol by 25-hydroxylase in the liver
  • 25-hydroxycholecalciferiol is hydroxylated to 1,25-hydroxycholecalciferol by a-hydroxylase in the kidneys.
  • Parathyroid hormone and cAMP promote this last step by stimulating 1a-hydroxylase
  • Calcium, phosphate and FGF23 inhibit 1a-hydroxylase
22
Q

Why do you not give iron during an infection?

A
  • During bacterial infection, pathogen and host compete for iron (Fe). The inflammatory response associated with infection shifts Fe from the circulation into storage, resulting in hypoferremia and iron-deficient erythropoiesis, and ultimately contributing to the anemia of inflammation.
  • Bacteria employ both membrane-bound transferrin receptors and high-affinity iron-binding proteins called siderophores to acquire Fe, eg: Pseudomonas especially.
  • Humans utilize the iron-binding proteins lactoferrin, transferrin, and ferritin to move Fe away from sites of infection and into storage. Synthesis and action of these proteins are regulated by inflammatory cytokines.
  • Iron overload leads to inhibition of IFN-gamma, TNF-alpha, IL-12, and nitric oxide formation as well as impairment of macrophage, neutrophil, and T-cell function.
23
Q

What cancer is Balkan endemic nephropathy associated with?

A

Transitional cell carcinoma

24
Q

How is haemoglobinuria distinguished from true haematuria?

A

Haemoglobinuria is distinguished from true haematuria by the absence of erythrocytes on urine microscopy

25
Q

AL Amyloidosis characteristics

A
  • AL amyloidosis occurs secondary to plasma cell dyscrasia
  • Infiltration into different organs - restrictive cardiomyopathy, peripheral neuropathy, hepatosplenomegaly, cutaneous purpura, macroglossia, nephrotic range proteinuria
26
Q

GBM clinical features

A
  • Inherited type IV
  • Characterised by microscopic or macroscopic hematuria
  • Diagnosis - history of persistent haematuria, normal kidney function and positive fam hx of haematuria without kidney failure
  • Biopsy not typically required
27
Q

Fabry Disease

A
  • X linked inherited disorder
  • deficiency of a galactosidase A - enzyme in the glycosphingolipid pathway
  • Deposits of Gb3 in lyosomes
28
Q

Function of loop diuretics

A

Loop diuretics are not filtered as they are protein bound and are secreted by Organic Acid Transporters (OAT) in the proximal tubule. Block Na absorption in thick ascending loop of henle.

29
Q

In patients with a sulphur allergy, what diuretic can be used?

A

Ethacrynic acid is a loop diuretic which does not contain a sulpha moiety and so can be used in patients who have a Sulphur allergy.

30
Q

A 34-year-old woman presents 8 months post hypertensive pregnancy with nephrotic range proteinuria and ongoing hypertension. She proceeds to renal biopsy, which demonstrates IgG deposition along the basement membrane and C4D+. Her PLA2R returns a positive result and her renal function is normal. She has 3.5g of proteinuria a day. How would you manage her in this initial period?
A. Pulse steroids followed by prednisone 1mg/kg daily for 6 months
B. Rituximab infusion 100mg two doses 6 weeks apart
C. Maximum ACEI or angiotensin receptor blockade for 6 months
D. Cyclophosphamide and steroids in a modified Pontichelli regime

A

C. Maximum ACEI or angiotensin receptor blockade for 6 months

This clinical picture is consistent with membranous nephropathy with low risk features. Spontaneous remission is possible in the 1st 6 months and there is no indication to aggressively immunosuppress at this stage.